Help
RSS
API
Feed
Maltego
Contact
Domain > www.onapgohcp.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2024-11-05
23.219.87.209
(
ClassC
)
2024-11-06
23.223.240.195
(
ClassC
)
2025-11-15
23.41.4.85
(
ClassC
)
Port 443
HTTP/1.1 200 OKContent-Type: text/html; charsetUTF-8Content-Language: enX-Content-Type-Options: nosniffX-Frame-Options: SAMEORIGINX-Generator: Drupal 10 (https://www.drupal.org)X-Consumer-ID: 7843a489-667a-4bdf-b8e4-f5617fe1d20fStrict-Transport-Security: max-age63072000; includeSubDomainsX-Request-ID: v-b52c7e9e-c265-11f0-b5b4-23c487f0e837X-AH-Environment: 01liveX-Age: 0Cache-Control: private, no-cache, must-revalidateExpires: Sat, 15 Nov 2025 20:59:03 GMTDate: Sat, 15 Nov 2025 20:59:03 GMTTransfer-Encoding: chunkedConnection: keep-aliveConnection: Transfer-Encoding !DOCTYPE html>html langen dirltr prefixog: https://ogp.me/ns#> head> meta charsetutf-8 />meta namedescription contentDiscover ONAPGO™ (apomorphine HCl) injection, for subcutaneous infusion. ONAPGO is the first and only minimally invasive treatment for Parkinson’s disease. />link relcanonical hrefhttps://www.onapgohcp.com/ />link relshortlink hrefhttps://www.onapgohcp.com/ />meta propertyog:site_name contentONAPGO™ -A Wearable Device for Parkinson’s Disease />meta propertyog:title contentONAPGO™ - A Wearable Device for Parkinson’s Disease />meta propertyog:description contentDiscover ONAPGO (apomorphine HCI) injection, for subcutaneous infusion. ONAPGO is the first and only minimally invasive treatment for Parkinson’s disease. />script typetext/javascript>var cookiehandlersettings {cookiebanner_expire:-1,forcedmodal_expire:-1};/script>script typetext/javascript>/*✅ Site admin path: /admin/config/development/mvp-website-support/interaction-studio-handler✅ Interaction Studio JavaScript beacon: //cdn.evgnet.com/beacon/supernuspharma/supernus_dev/scripts/evergage.min.js✅ Asynchronous integration✅ Clear cache: /admin/config/development/performance*/var sf;function init_issitewidejavascript() { sf SalesforceInteractions; sf.init({}).then(() > { const sitemapConfig { global: { onActionEvent: (actionEvent) > { // We really dont care about lowercasing the value so we can just lowercase the entire search variable const params new URLSearchParams( window.location.search.toLowerCase() ); actionEvent.user actionEvent.user || {}; actionEvent.user.attributes actionEvent.user.attributes || {}; var sfmcID params.has(sfmcid) ? params.get(sfmcid) : ; if (sfmcID) { actionEvent.user.attributes.sfmcContactKey sfmcID; } actionEvent.user.attributes.brand ONAPGO; actionEvent.user.attributes.webEngagement ONAPGO: HCP_Branded; actionEvent.user.attributes.audience HCP_Branded; return actionEvent; }, }, pageTypeDefault: { // This matches any page that isnt matched below name: default, interaction: { name: document.title, }, }, pageTypes: { // HOMEPAGE name: ONAPGO HCP Homepage, isMatch: () > /^\/$/.test(window.location.pathname), interaction: { name: View ONAPGO HCP Homepage, }, }, { // SIGN UP name: ONAPGO HCP Signup Page, isMatch: () > /^\/sign-up\/?$/.test(window.location.pathname), interaction: { name: View ONAPGO HCP Signup Page, }, }, , }; sf.initSitemap(sitemapConfig); });}function sitewideSuccessTracking(frm) { if (typeof sf ! undefined) { var formId frm.attr(id); // Sign up for updates if (/onapgo-sign-up-hcp-form/g.test(formId)) { sf.sendEvent({ interaction: { name: Sign Up ONAPGO HCP Signup Page, }, user: { identities: { emailAddress: frm.find(inputnametxt_field_email).val(), }, attributes: { firstName: frm.find(inputnametxt_field_first_name).val(), lastName: frm.find(inputnametxt_field_last_name).val(), }, }, }); } else if (/instructions-for-use-hcp-form/g.test(formId)) { sf.sendEvent({ interaction: { name: Sign Up ONAPGO HCP Instructions For Use, }, user: { // For some reason the NPI appears to be in two locations in the Interaction Studio configuration. I dont think it hurts to store it in both locations so Im just going to do that for now identities: { hcpNpiNumber: frm.find(inputnamenpi_id_number).val(), }, attributes: { hcpNpiNumber: frm.find(inputnamenpi_id_number).val(), firstName: frm.find(inputnamefirstname).val(), lastName: frm.find(inputnamelastname).val(), }, }, }); } }}/script>script typetext/javascript src//cdn.evgnet.com/beacon/supernuspharma/supernus_prod/scripts/evergage.min.js asyncasync>/script>meta nameGenerator contentDrupal 10 (https://www.drupal.org) />meta nameMobileOptimized contentwidth />meta nameHandheldFriendly contenttrue />meta nameviewport contentwidthdevice-width, initial-scale1, shrink-to-fitno />meta nameformat-detection contenttelephoneno>meta http-equivx-ua-compatible contentieedge />link relicon href/sites/g/files/othskp1921/files/Onapgo_Favicon_x2_1.png typeimage/png /> title>ONAPGO™ (apomorphine HCl) - A Wearable Device for Parkinson’s Disease/title> link relstylesheet mediaall href/sites/g/files/othskp1921/files/css/css__KqrIHAj9S2fdogcu8aqMkFtv88tKyOYvr6ZiA9gz0E.css?delta0&languageen&themeonapgohcp_theme&includeeJx1j10OAiEMhC-Ey5FIWSpgCm0ouO7t1Y0_icSXPsw3bWc8c9feQJyH1jLbM9cOGyoXNH6GrcxqJPZAJ-075RpnXlAVIqqjHFOfeeWAZuWGNrQhQAtc4Ga4gkROq7iesOARTI1Ag_jYTfo2f5VlVBmesiYMRodgq0OdEPRn7teZz_e_jp86umvHYj0ommvGTe0xl8JhEN4BTiF_wQ />link relstylesheet mediaall href/sites/g/files/othskp1921/files/css/css_L1BJM3_hKeBAoB8XWie7dBNiUiGY5zqg1FdoTRSQ4Ks.css?delta1&languageen&themeonapgohcp_theme&includeeJx1j10OAiEMhC-Ey5FIWSpgCm0ouO7t1Y0_icSXPsw3bWc8c9feQJyH1jLbM9cOGyoXNH6GrcxqJPZAJ-075RpnXlAVIqqjHFOfeeWAZuWGNrQhQAtc4Ga4gkROq7iesOARTI1Ag_jYTfo2f5VlVBmesiYMRodgq0OdEPRn7teZz_e_jp86umvHYj0ommvGTe0xl8JhEN4BTiF_wQ />link relstylesheet mediaall href//use.fontawesome.com/releases/v5.13.0/css/all.css />link relstylesheet mediaall href/sites/g/files/othskp1921/files/css/css_l7zKugxbeQsivIqfde2MzFxFtbhfj9LmhwCxXuf2QXo.css?delta3&languageen&themeonapgohcp_theme&includeeJx1j10OAiEMhC-Ey5FIWSpgCm0ouO7t1Y0_icSXPsw3bWc8c9feQJyH1jLbM9cOGyoXNH6GrcxqJPZAJ-075RpnXlAVIqqjHFOfeeWAZuWGNrQhQAtc4Ga4gkROq7iesOARTI1Ag_jYTfo2f5VlVBmesiYMRodgq0OdEPRn7teZz_e_jp86umvHYj0ommvGTe0xl8JhEN4BTiF_wQ />link relstylesheet mediaprint href/sites/g/files/othskp1921/files/css/css_6VLtXGHhHPEtX4jP-tqizEHxPgm0Akpp_ZtQEzeQrbU.css?delta4&languageen&themeonapgohcp_theme&includeeJx1j10OAiEMhC-Ey5FIWSpgCm0ouO7t1Y0_icSXPsw3bWc8c9feQJyH1jLbM9cOGyoXNH6GrcxqJPZAJ-075RpnXlAVIqqjHFOfeeWAZuWGNrQhQAtc4Ga4gkROq7iesOARTI1Ag_jYTfo2f5VlVBmesiYMRodgq0OdEPRn7teZz_e_jp86umvHYj0ommvGTe0xl8JhEN4BTiF_wQ />link relstylesheet mediaall hrefhttps://use.typekit.net/mud2bcf.css /> script typeapplication/json data-drupal-selectordrupal-settings-json>{path:{baseUrl:\/,pathPrefix:,currentPath:node\/141,currentPathIsAdmin:false,isFront:true,currentLanguage:en},pluralDelimiter:\u0003,suppressDeprecationErrors:true,gtag:{tagId:,consentMode:false,otherIds:,events:,additionalConfigInfo:},ajaxPageState:{libraries:eJx1UNGOwyAM-yEG0v0QCmtG6QXCSOiuf3-sk266dXuxFDtKbAdmFW1QfYDWErsLF4UbCmc04Si2fGQjcQA6iW6USjzqGUUgonhKcdajXnhCc-aGLhXFVoDscu3YNrv_i8yR0CtEFwe8zhYW-PlPZpPX6iuB3g_4O8juXfz65Rd5J3dNlDQNl0PnAjXyfK5eZ8y4l3JkHyZPGeTbVGgQR6ZZ3NR6HRGejO2l9kBJZpyM9Doidnn-fxz7a-XjxkvNn9Yq03ZJRGJkE8XsAgiaNeFN3I4289QJfwFlFsmY,theme:onapgohcp_theme,theme_token:null},ajaxTrustedUrl:{form_action_p_pvdeGsVG5zNF_XLGPTvYSKCf43t8qZYSwcfZl2uzM:true,\/home?ajax_form1:true},gtm:{tagId:null,settings:{data_layer:dataLayer,include_environment:false},tagIds:GTM-WB2W7WC},ajax:{edit-validation-hack:{callback:{},setMessage,event:click,progress:{type:throbber,message:},url:\/home?ajax_form1,httpMethod:POST,dialogType:ajax,submit:{_triggering_element_name:op,_triggering_element_value:validated}}},user:{uid:0,permissionsHash:9a4ffffbe1fe3782b7274e1dbba034aa13d2dc1fa92bab11b861a3860cd15748}}/script>script src/sites/g/files/othskp1921/files/js/js_cS9lk6i6cxYpOmRKLcC1auWv2M954lVhAPGkG4BBV48.js?scopeheader&delta0&languageen&themeonapgohcp_theme&includeeJx1j-EKgzAMhF-oWtgLhVRqrUubrkllvv10MsZk_vkgueO4c8wqWrGAw1oj20DskDrRlWIOZuDqbczqa0bq50fzde1HrskE5kAeFIMNG853jzM-f5_JpKVAIdQ9AHaIfROWG8zyT24aKWr0suucsQSehgI6-eTtUadLKHcjrWwdm3wDDo_7DLx0nBZf2QrTOkYieQH_K3p7>/script>script src/modules/contrib/google_tag/js/gtag.js?t4jx2k>/script>script src/modules/contrib/google_tag/js/gtm.js?t4jx2k>/script> /head> body classlayout-no-sidebars page-node-141 onapgo-audience-hcp path-frontpage node--type-component-page> a href#main-content classvisually-hidden focusable skip-link> Skip to main content /a> noscript>iframe srchttps://www.googletagmanager.com/ns.html?idGTM-WB2W7WC height0 width0 styledisplay:none;visibility:hidden>/iframe>/noscript> div classdialog-off-canvas-main-canvas data-off-canvas-main-canvas> div idpage-wrapper> div idpage> section classrow region region-warning-scripts> div idblock-onapgohcp-theme-spnjscookiewarning data-block-plugin-idblock_content:70741230-ad14-4315-b858-fd38533be4ae classblock block-block-content block-block-content70741230-ad14-4315-b858-fd38533be4ae component-banner-jscookie-warning> div classrow> div classcol> div classcontent> div classclearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item>p classtext-align-center px-2 p-small>This site requires JavaScript and cookies to be enabled./p>/div> /div> /div> /div>/div>noscript idblock-onapgohcp-theme-spnjscookiewarning data-block-plugin-idblock_content:70741230-ad14-4315-b858-fd38533be4ae classblock block-block-content block-block-content70741230-ad14-4315-b858-fd38533be4ae component-banner-jscookie-warning noscript> div classrow> div classcol> div classcontent> div classclearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item>p classtext-align-center px-2 p-small>This site requires JavaScript and cookies to be enabled./p>/div> /div> /div> /div>/noscript>div idblock-onapgohcp-theme-opnagohcpcookiebanner data-block-plugin-idblock_content:0c7fe022-6f78-40f2-bc5f-9edd231d2b56 classblock block-block-content block-block-content0c7fe022-6f78-40f2-bc5f-9edd231d2b56 component-banner-cookie container-fluid> button classclose component-banner-cookie--close-btn typebutton data-actionclose-banner aria-labelClose > span aria-hiddentrue>×/span> /button> div classinner-content-wrapper> div classrow> div classcol> div classcontent> h3 classcomponent-banner-cookie--title d-none> div classfield field--name-field-title field--type-string field--label-hidden field__item>OpnagoHCP - Cookie Banner/div> /h3> div classd-md-flex> div classcomponent-banner-cookie--body> div classclearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item>p classmb-0 text-center text-md-left p-0 col-md-10 f-lh-20>This website stores data, such as cookies, to enable important site functionality including analytics, targeting, and personalization./p>/div> /div> div classcomponent-banner-cookie--footer> div classcomponent-banner-cookie--button-container component-banner-cookie--button-container-secondary> div classfield field--name-field-p-secondary-button field--type-entity-reference-revisions field--label-hidden field__item> div classparagraph paragraph--type--partial-button paragraph--view-mode--default> div classfield field--name-field-link-button field--type-link field--label-hidden field__item>a hrefhttps://www.supernus.com/cookies-policy target_blank classp-0 btn-light btn>More Info /a>/div> /div>/div> /div> div classcomponent-banner-cookie--button-container component-banner-cookie--button-container-primary> button classbtn btn-light data-actionclose-banner > div classfield field--name-field-label-yes field--type-string field--label-hidden field__item>Accept/div> /button> /div> /div> /div> /div> /div> /div> /div>/div> /section> header idheader classheader component-masthead rolebanner aria-labelSite header> nav classnavbar bg-transparent navbar-utility--wrapper idnavbar-top> div classinner-content-wrapper> div classnavbar-utility--menu-container> div classnav-group navbar-utility--desktop> section classrow region region-utility-navigation> nav rolenavigation aria-labelledbyblock-onapgohcp-theme-onapgohcputilitynavigation-menu idblock-onapgohcp-theme-onapgohcputilitynavigation data-block-plugin-idsystem_menu_block:main classblock block-menu navigation menu--main> h2 classsr-only idblock-onapgohcp-theme-onapgohcputilitynavigation-menu>Onapgo HCP - Utility Navigation/h2> ul data-regionutility_navigation blockblock-onapgohcp-theme-onapgohcputilitynavigation regionutility_navigation classclearfix nav navbar-nav> li classnav-item> a href#region-inline-isi classmr-md-4 nav-link nav-link-region-inline-isi>Important Safety Information/a> /li> li classnav-item> a href/onapgo_PI.pdf target_blank classnav-link nav-link--onapgo-pipdf data-drupal-link-system-pathpath-file/11>Full Prescribing Information/a> /li> li classnav-item> a href/onapgo-resources#instructions-for-use classnav-link nav-link--onapgo-resourcesinstructions-for-use data-drupal-link-system-pathnode/136>Instructions for Use/a> /li> li classnav-item> a hrefhttps://www.onapgo.com/ target_blank classnav-link nav-link-https---customconsumer-domain->Patient Sitei classicon-onapgo-arrow-top-right nav-icon>/i>/a> /li> /ul> /nav> /section> /div> div classnav-group navbar-utility--mobile> section classrow region region-utility-navigation-mobile> nav rolenavigation aria-labelledbyblock-onapgohcp-theme-onapgohcputilitynavigationmobile-menu idblock-onapgohcp-theme-onapgohcputilitynavigationmobile data-block-plugin-idsystem_menu_block:spn---main-navigation-mobile classblock block-menu navigation menu--spn---main-navigation-mobile> h2 classsr-only idblock-onapgohcp-theme-onapgohcputilitynavigationmobile-menu>Onapgo HCP - Utility Navigation Mobile/h2> ul data-regionutility_navigation_mobile blockblock-onapgohcp-theme-onapgohcputilitynavigationmobile regionutility_navigation_mobile classclearfix nav navbar-nav> li classnav-item menu-item--expanded dropdown> a href classnav-link dropdown-toggle nav-link- data-toggledropdown aria-expandedfalse aria-haspopuptrue>Full Prescribing Information/a> ul classdropdown-menu> li classdropdown-item> a href#region-inline-isi classnav-link-region-inline-isi>Important Safety Information/a> /li> li classdropdown-item> a href/onapgo_PI.pdf target_blank classnav-link--onapgo-pipdf data-drupal-link-system-pathpath-file/11>Full Prescribing Information/a> /li> li classdropdown-item> a href/onapgo-resources#instructions-for-use classnav-link--onapgo-resourcesinstructions-for-use data-drupal-link-system-pathnode/136>Instructions for Use/a> /li> li classdropdown-item> a hrefhttps://www.onapgo.com/ target_blank classnav-link-https---customconsumer-domain->Patient Sitei classicon-onapgo-arrow-top-right nav-icon>/i>/a> /li> /ul> /li> /ul> /nav> /section> /div> /div> /div> /nav> nav classnavbar navbar-light bg-white navbar-expand-lg navbar-main idnavbar-main> div classinner-content-wrapper> div classnavbar-main--top> div classnavbar-main--top-left> section classrow region region-header> a href/ titleONAPGO™ (apomorphine HCl) injection, for subcutaneous infusion 4.9 mg/mL relhome classnavbar-brand> img src/sites/g/files/othskp1921/files/ONAPGO-HCP-logo_desktop_0.png altONAPGO™ (apomorphine HCl) injection, for subcutaneous infusion 4.9 mg/mL classimg-fluid d-inline-block align-top /> /a> /section> button classnavbar-toggler navbar-toggler-right navbar-main--main-nav-toggler collapsed typebutton data-togglecollapse data-target#CollapsingNavbar aria-controlsCollapsingNavbar aria-expandedfalse aria-labelToggle navigation >span classnavbar-toggler-icon>/span>/button> /div> div classform-inline navbar-main--top-right> section classrow region region-header-form> nav rolenavigation aria-labelledbyblock-onapgohcp-theme-optionallinks-menu idblock-onapgohcp-theme-optionallinks data-block-plugin-idsystem_menu_block:optional-links classblock block-menu navigation menu--optional-links> h2 classsr-only idblock-onapgohcp-theme-optionallinks-menu>Optional Links/h2> ul data-regionheader_form blockblock-onapgohcp-theme-optionallinks regionheader_form classclearfix nav> li classnav-item> a href/sign-up classbtn btn-secondary-light-blue small f-size-18 f-lh-22 text-uppercase nav-link btnbtn-secondary-light-bluesmallf-size-18f-lh-22text-uppercase nav-link--sign-up data-drupal-link-system-pathnode/146>GET UPDATES/a> /li> li classnav-item> a href/request-a-supernus-representative classbtn btn-primary f-size-18 f-lh-22 small text-uppercase nav-link btnbtn-primaryf-size-18f-lh-22smalltext-uppercase nav-link--request-a-supernus-representative data-drupal-link-system-pathnode/171>Request a rep/a> /li> /ul> /nav> /section> /div> /div> div classnavbar-main--bottom> div classcollapse navbar-collapse navbar-main--nav idCollapsingNavbar> nav rolenavigation aria-labelledbyblock-onapgohcp-theme-hcpprimarynavigationmenu-menu idblock-onapgohcp-theme-hcpprimarynavigationmenu data-block-plugin-idsystem_menu_block:hcp---primary-navigation-menu classblock block-menu navigation menu--hcp---primary-navigation-menu> h2 classsr-only idblock-onapgohcp-theme-hcpprimarynavigationmenu-menu>HCP - Primary Navigation menu/h2> ul data-regionprimary_menu blockblock-onapgohcp-theme-hcpprimarynavigationmenu regionprimary_menu classclearfix nav navbar-nav> li classnav-item> a href/request-a-supernus-representative classd-lg-none symbol-right-arrow gray-arrow nav-link d-lg-none symbol-right-arrow gray-arrow nav-link--request-a-supernus-representative data-drupal-link-system-pathnode/171>Request a Representative /a> /li> li classnav-item active> a href/home classnav-link active nav-link--home is-active data-drupal-link-system-pathnode/141 aria-currentpage>Home/a> /li> li classnav-item> a href/about-onapgo classnav-link nav-link--about-onapgo data-drupal-link-system-pathnode/131>About ONAPGO/a> /li> li classnav-item> a href/efficacy-and-safety classnav-link nav-link--efficacy-and-safety data-drupal-link-system-pathnode/201>Efficacy & Safety/a> /li> li classnav-item> a href/getting-started classnav-link nav-link--getting-started data-drupal-link-system-pathnode/206>Getting Started/a> /li> li classnav-item> a href/onapgo-resources classnav-link nav-link--onapgo-resources data-drupal-link-system-pathnode/136>Resources/a> /li> /ul> /nav> /div> /div> /div> /nav> /header> div classhighlighted> aside classcontainer-fluid section clearfix rolecomplementary> div idblock-onapgohcp-theme-signupforupdates-2 data-block-plugin-idblock_content:240761db-b8e8-40c0-a11d-dcf9db22629f classblock block-block-content block-block-content240761db-b8e8-40c0-a11d-dcf9db22629f> div classcontent> div classfield field--name-field-p-block-content-flex field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item>style> #paragraph_component_bg_container_n_23001 > .bg { background-color: #BBDAEB; } @media screen and (max-width: 767px){ #paragraph_component_bg_container_n_23001 .bg img{ object-position: center; } } @media screen and (min-width: 768px) and (max-width: 991px) { #paragraph_component_bg_container_n_23001 .bg img{ object-position: center; } } @media screen and (min-width: 992px) { #paragraph_component_bg_container_n_23001 .bg img{ object-position: center; } }/style>div classparagraph paragraph--type--component-background-container paragraph--view-mode--default component-background-container d-lg-none > div classbg-container classparagraph paragraph--type--component-background-container paragraph--view-mode--default component-background-container d-lg-none idparagraph_component_bg_container_n_23001> div classbg > /div> div classfield field--name-field-p-background-comp-content field--type-entity-reference-revisions field--label-hidden field__item>div classparagraph paragraph--type--partial-background-content paragraph--view-mode--default partial-background-content bg-content> div classbg-content-wrapper> div classfield field--name-field-p-background-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classparagraph paragraph--type--component-html-container paragraph--view-mode--default component-html-container > div classclearfix text-formatted field field--name-field-text-html field--type-text-long field--label-hidden field__item>a classsign-up-mobile data-drupal-link-system-pathnode/146 href/sign-up>GET UPDATES/a>/div> /div>/div> /div> /div>/div> /div> /div>/div>/div> /div> /div> /div> /aside> /div> div idmain-wrapper classlayout-main-wrapper clearfix> div idmain classcontainer-fluid> div classrow row-offcanvas row-offcanvas-left clearfix> main classmain-content col idcontent rolemain> section classsection> a idmain-content tabindex-1>/a> div data-drupal-messages-fallback classhidden>/div>div idblock-onapgohcp-theme-mainpagecontent data-block-plugin-idsystem_main_block classblock block-system block-system-main-block> div classcontent> article classnode node--type-component-page node--promoted node--view-mode-full clearfix> header> /header> div classnode__content clearfix> div classfield field--name-field-p-components-container field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item>style> @media screen and (max-width: 767px){ #paragraph_component_bg_container_n_25831 .bg img{ object-position: center; } #paragraph_component_bg_container_n_25831.bg-container { min-height: 260px; } } @media screen and (min-width: 768px) and (max-width: 991px) { #paragraph_component_bg_container_n_25831 .bg img{ object-position: center; } #paragraph_component_bg_container_n_25831.bg-container { min-height: 370px; } } @media screen and (min-width: 992px) { #paragraph_component_bg_container_n_25831 .bg img{ object-position: center; } #paragraph_component_bg_container_n_25831.bg-container { min-height: 370px; } }/style>div classparagraph paragraph--type--component-background-container paragraph--view-mode--default component-background-container hero-hcp hero-hcp--img-xxlg-contain hero-tablet-relative mb-6 > div classbg-container content-flex classparagraph paragraph--type--component-background-container paragraph--view-mode--default component-background-container hero-hcp hero-hcp--img-xxlg-contain hero-tablet-relative mb-6 idparagraph_component_bg_container_n_25831> div classbg > div classparagraph paragraph--type--partial-swapping-image paragraph--view-mode--default component-image-swapping> picture> source media(min-width: 992px) srcset/sites/g/files/othskp1921/files/2025-02/HCP-Homepage-Header_desktop_3.png> source media(min-width: 768px) srcset/sites/g/files/othskp1921/files/2025-02/HCP-Homepage-Header_mobile_2x_0.png> source media(min-width: 0px) srcset/sites/g/files/othskp1921/files/2025-02/HCP-Homepage-Header_mobile_2x_0.png> img src/sites/g/files/othskp1921/files/2025-02/HCP-Homepage-Header_mobile_2x_0.png altGo on with Onapgo™. All photos within this website are actor portrayals classbg > /picture> /div> /div> div classfield field--name-field-p-background-comp-content field--type-entity-reference-revisions field--label-hidden field__item>div classparagraph paragraph--type--partial-background-content paragraph--view-mode--default partial-background-content bg-content> div classbg-content-wrapper> div classfield field--name-field-p-background-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classcomponent-responsive-columns paragraph paragraph--type--component-responsive-columns paragraph--view-mode--default mt-md-4 mt-lg-5 > div classinner-content-wrapper > div classrow field__items > div classpartial-responsive-column col col-lg-7 paragraph paragraph--type--partial-responsive-column paragraph--view-mode--default> div classfield field--name-field-p-column-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item>div classparagraph paragraph--type--component-image paragraph--view-mode--default component-image > style> /style> div classcontainer-overlay mb-3 mb-md-0 classparagraph paragraph--type--component-image paragraph--view-mode--default component-image idparagraph_component_image_n_25726> div classbg > div classfield field--name-field-p-image field--type-entity-reference-revisions field--label-hidden field__item>div classcomponent-scalling-image>/div>/div> /div> /div>/div>/div> /div> /div> div classpartial-responsive-column col-12 col-md-12 col-lg-5 paragraph paragraph--type--partial-responsive-column paragraph--view-mode--default> div classfield field--name-field-p-column-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classparagraph paragraph--type--component-html-container paragraph--view-mode--default component-html-container > div classclearfix text-formatted field field--name-field-text-html field--type-text-long field--label-hidden field__item>p classf-size-18 f-lh-22 c-color-black mt-lg-n2>span classc-color-blue font-weight-700 mt-3>The first and only continuous subcutaneous/span> apomorphine infusion that can provide more consistent control of motor fluctuations in patients with advanced Parkinson’s disease.sup>1/sup>/p>a classbtn btn-primary text-uppercase href/about-onapgo>About ONAPGO/a>/div> /div>/div> /div> /div> /div> /div> /div>/div> /div> /div>/div> /div> /div>/div>/div> div classfield__item> div classcomponent-responsive-columns paragraph paragraph--type--component-responsive-columns paragraph--view-mode--default mb-4 mb-md-6 > div classinner-content-wrapper > div classrow field__items > div classpartial-responsive-column col-12 d-flex justify-content-center col-md-12 col-lg-12 paragraph paragraph--type--partial-responsive-column paragraph--view-mode--default> div classfield field--name-field-p-column-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classcomponent-cta paragraph paragraph--type--component-cta paragraph--view-mode--default cta-custom-column > style> #paragraph_component_cta_n_21411 .cta-image img, #paragraph_component_cta_n_21411 .cta-image svg { max-width: 200px; } @media screen and (min-width: 768px) { #paragraph_component_cta_n_21411 .cta-image img, #paragraph_component_cta_n_21411 .cta-image svg { max-width: 225px; } } @media screen and (min-width: 992px) { #paragraph_component_cta_n_21411 .cta-image img, #paragraph_component_cta_n_21411 .cta-image svg { max-width: 225px; } } /style> div classrow> div idparagraph_component_cta_n_21411 classcta-container col> div classrow> div classcta-image col-12> img loadinglazy src/sites/g/files/othskp1921/files/styles/sp_max_780px_1x/public/2024-10/An-old-man-holding-ONAPGO_desktop.png?itoklbzQTPAd width452 height452 alt classimage-style-sp-max-780px-1x /> /div> div classcta-body col-12 > div classclearfix text-formatted field field--name-field-cta-body field--type-text-long field--label-hidden field__item>h2 classmt-4 mt-md-0 c-color-blue font-weight-400 f-size-28 h3 f-lh-34 text-uppercase>Established History— br>Proven Results/h2>p classmb-3 >For 30 years, clinicians in Europe have used continuous subcutaneous apomorphine infusion to deliver more consistent control of motor fluctuations for thousands of patients.sup>2,3/sup>/p>a href/efficacy-and-safety classfont-weight-700 btn btn-primary text-uppercase>see results/a>/div> /div> /div> /div> /div> /div>/div> /div> /div> /div> /div> /div>/div> div classfield__item> div classcomponent-responsive-columns paragraph paragraph--type--component-responsive-columns paragraph--view-mode--default cta-custom-column-parent mb-4 mb-md-6 > div classinner-content-wrapper > div classrow field__items > div classpartial-responsive-column col-12 d-flex justify-content-center col-md-12 col-lg-12 paragraph paragraph--type--partial-responsive-column paragraph--view-mode--default> div classfield field--name-field-p-column-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classcomponent-cta paragraph paragraph--type--component-cta paragraph--view-mode--default cta-custom-column > style> #paragraph_component_cta_n_21151 .cta-image img, #paragraph_component_cta_n_21151 .cta-image svg { max-width: 200px; } @media screen and (min-width: 768px) { #paragraph_component_cta_n_21151 .cta-image img, #paragraph_component_cta_n_21151 .cta-image svg { max-width: 225px; } } @media screen and (min-width: 992px) { #paragraph_component_cta_n_21151 .cta-image img, #paragraph_component_cta_n_21151 .cta-image svg { max-width: 225px; } } /style> div classrow> div idparagraph_component_cta_n_21151 classcta-container col> div classrow> div classcta-image col-12> img loadinglazy src/sites/g/files/othskp1921/files/styles/sp_max_780px_1x/public/2024-10/Two-doctors-talking_desktop_0.png?itokBYDdwQoV width452 height452 alt classimage-style-sp-max-780px-1x /> /div> div classcta-body col-12 > div classclearfix text-formatted field field--name-field-cta-body field--type-text-long field--label-hidden field__item>h2 classmt-4 mt-md-0 c-color-blue font-weight-400 f-size-28 h3 f-lh-34 text-uppercase>GET YOUR PATIENTS STARTED ON ONAPGO/h2>p classmb-3 >Review the comprehensive support and how to prescribe for your appropriate patients.sup>4/sup>/p>a href/getting-started classfont-weight-700 btn btn-primary text-uppercase>STARTING ONAPGO/a>/div> /div> /div> /div> /div> /div>/div> /div> /div> /div> /div> /div>/div> div classfield__item>style> #paragraph_component_bg_container_n_26126 > .bg { background-color: #F2F2F2; } @media screen and (max-width: 767px){ #paragraph_component_bg_container_n_26126 .bg img{ object-position: center; } } @media screen and (min-width: 768px) and (max-width: 991px) { #paragraph_component_bg_container_n_26126 .bg img{ object-position: center; } #paragraph_component_bg_container_n_26126.bg-container { min-height: 200px; } } @media screen and (min-width: 992px) { #paragraph_component_bg_container_n_26126 .bg img{ object-position: center; } #paragraph_component_bg_container_n_26126.bg-container { min-height: 200px; } }/style>div classparagraph paragraph--type--component-background-container paragraph--view-mode--default component-background-container > div classbg-container classparagraph paragraph--type--component-background-container paragraph--view-mode--default component-background-container idparagraph_component_bg_container_n_26126> div classbg > /div> div classfield field--name-field-p-background-comp-content field--type-entity-reference-revisions field--label-hidden field__item>div classparagraph paragraph--type--partial-background-content paragraph--view-mode--default partial-background-content bg-content> div classpy-md-5 py-5 pb-md-0 bg-content-wrapper> div classfield field--name-field-p-background-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classcomponent-responsive-columns paragraph paragraph--type--component-responsive-columns paragraph--view-mode--default gray-column-home border-left-green-child > div classinner-content-wrapper > div classrow field__items > div classpartial-responsive-column col-12 d-flex justify-content-center col-md-4 col-lg-4 paragraph paragraph--type--partial-responsive-column paragraph--view-mode--default> div classfield field--name-field-p-column-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classparagraph paragraph--type--component-html-container paragraph--view-mode--default component-html-container > div classclearfix text-formatted field field--name-field-text-html field--type-text-long field--label-hidden field__item>h2 classc-color-blue font-weight-400 f-size-28 h3 f-lh-34 text-uppercase>REQUEST A REP/h2>p>Talk to a Supernus representative to learn more about ONAPGO./p>/div> /div>/div> div classfield__item> div classparagraph paragraph--type--partial-button paragraph--view-mode--default> div classfield field--name-field-link-button field--type-link field--label-hidden field__item>a href/request-a-supernus-representative classtext-uppercase btn btn-primary>SUBMIT REQUEST/a>/div> /div>/div> /div> /div> div classpartial-responsive-column col col-md-3 col-lg-3 paragraph paragraph--type--partial-responsive-column paragraph--view-mode--default> /div> div classpartial-responsive-column col-12 d-flex justify-content-center col-md-4 col-lg-4 paragraph paragraph--type--partial-responsive-column paragraph--view-mode--default> div classfield field--name-field-p-column-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classparagraph paragraph--type--component-html-container paragraph--view-mode--default component-html-container > div classclearfix text-formatted field field--name-field-text-html field--type-text-long field--label-hidden field__item>h2 classc-color-blue font-weight-400 f-size-28 h3 f-lh-34 text-uppercase>GET UPDATES/h2>p>Sign up to get the latest news and information about ONAPGO./p>/div> /div>/div> div classfield__item> div classparagraph paragraph--type--partial-button paragraph--view-mode--default> div classfield field--name-field-link-button field--type-link field--label-hidden field__item>a href/sign-up classtext-uppercase btn btn-primary>REGISTER NOW/a>/div> /div>/div> /div> /div> /div> /div> /div>/div> /div> /div>/div> /div> /div>/div>/div> /div> /div>/article> /div> /div>div idblock-onapgohcp-theme-backtotopbutton data-block-plugin-idblock_content:3f296900-f405-4102-ada1-a6ec0e348e28 classblock block-block-content block-block-content3f296900-f405-4102-ada1-a6ec0e348e28> div classcontent> div classfield field--name-field-p-block-content-flex field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classparagraph paragraph--type--component-html-container paragraph--view-mode--default component-html-container > div classclearfix text-formatted field field--name-field-text-html field--type-text-long field--label-hidden field__item>div classmb-0>button classarrow-top nav-link font-weight-700 text-uppercase border-0 href#header>Back to top/button>/div>/div> /div>/div> /div> /div> /div> /section> /main> /div> div idregion-inline-isi> div classinner-content-wrapper> section classrow region region-inline-isi> div idblock-onapgohcp-theme-content data-block-plugin-identity_block:node classblock block-entity-block block-entity-blocknode> div classcontent> article regioninline_isi classnode node--type-isi-page node--view-mode-inline clearfix component-isi> header> h2 classnode__title> span classfield field--name-title field--type-string field--label-hidden>IMPORTANT SAFETY INFORMATION/span> /h2> /header> div classnode__content clearfix> div classfield field--name-field-p-content field--type-entity-reference-revisions field--label-hidden field__item> div classparagraph paragraph--type--component-html-container paragraph--view-mode--default component-html-container > div classclearfix text-formatted field field--name-field-text-html field--type-text-long field--label-hidden field__item>div classshowContentSticky>p classc-color-blue mb-2 pr-3> strong> span classd-block d-sm-inline>IMPORTANT SAFETY INFORMATION/span> /strong>/p>p class> span classd-block c-color-blue mb-2>strong>CONTRAINDICATIONS/strong>/span>span classd-block mb-2> Concomitant use of ONAPGO with 5HTsub>3/sub> antagonists is contraindicated based on reports of profound hypotension and loss of consciousness span classbtn-read-more mb-3 rolebutton>Read More/span> /span>/p>/div>p class> span classd-block c-color-blue>strong>INDICATION/strong>/span>span classd-block> ONAPGO is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s Disease (PD)./span>/p>p classc-color-blue> strong>IMPORTANT SAFETY INFORMATION/strong>/p>p classc-color-blue mb-0> strong>CONTRAINDICATIONS/strong>/p>p> Concomitant use of ONAPGO with 5HTsub>3/sub> antagonists is contraindicated based on reports of profound hypotension and loss of consciousness when ONAPGO was administered with ondansetron./p>p> ONAPGO is contraindicated in patients who have demonstrated hypersensitivity/allergic/anaphylactic reaction to it or any of its excipients, including sulfite (i.e., sodium metabisulfite)./p>p classc-color-blue> strong>WARNINGS AND PRECAUTIONS/strong>/p>p> strong classc-color-green>Serious Adverse Reactions After Intravenous Administration:/strong> Subcutaneous use only; thrombus formation and pulmonary embolism have followed intravenous administration./p>p> strong classc-color-green>Nausea and Vomiting: /strong> ONAPGO is known to cause nausea and vomiting (may be severe) when administered at recommended doses. Antiemetics with anti-dopaminergic actions have the potential to worsen PD symptoms. Consider starting therapy, without antiemetics, at 1 mg and titrate based upon effectiveness and tolerance./p>p> strong classc-color-green>Falling Asleep During Activities of Daily Living (ADL) and Somnolence: /strong>Somnolence is commonly associated with ONAPGO. Before initiating treatment, advise patients of risk and assess for factors that can increase it. If significant daytime sleepiness develops or patients fall asleep during ADL, ONAPGO should ordinarily be stopped. If continued, advise patients not to drive and avoid other potentially dangerous activities. There is insufficient information to determine if dose reduction will eliminate episodes of falling asleep during ADL./p>p> strong classc-color-green>Syncope/Hypotension/Orthostatic Hypotension:/strong> ONAPGO may cause orthostatic hypotension at any time, but especially during dose escalation. Patients should avoid alcohol when using ONAPGO and lie down before and after taking sublingual nitroglycerin. Other vasodilators and antihypertensives may also increase hypotensive effects. Monitor blood pressure in patients taking concomitant antihypertensive medications or vasodilators./p>p> strong classc-color-green>Falls: /strong>Patients with PD are at risk of falling due to underlying postural instability, possible autonomic instability, and syncope caused by blood pressure lowering effects of PD drugs. ONAPGO may increase risk of falling by simultaneously lowering blood pressure and altering mobility./p>p> strong classc-color-green>Infusion Site Reactions and Infections: /strong> Reactions have been reported including nodules, erythema, hematomas, inflammation, pruritus, swelling, discoloration, hemorrhage, hypersensitivity, induration, edema, pain, rash, or bruising. If an infection is suspected, such as cellulitis, which was reported, the cannula should be removed from the infusion site and a new cannula placed at a new infusion site. In the event of a prolonged interruption of treatment with ONAPGO, the patient should be prescribed oral medications to treat their PD./p>p> strong classc-color-green>Hallucinations/Psychotic-Like Behavior: /strong> Patients with a major psychotic disorder should ordinarily not be treated with ONAPGO due to risk of exacerbating psychosis. Also, certain medications used to treat psychosis may exacerbate symptoms of PD and decrease effectiveness of ONAPGO./p>p>strong classc-color-green>Dyskinesia: /strong>ONAPGO may cause dyskinesia or exacerbate pre-existing dyskinesia./p>p> strong classc-color-green>Hemolytic Anemia: /strong>Hemolytic anemia requiring hospitalization has been reported. Many cases included positive Coombs test. Severe anemia, angina, and dyspnea have occurred. Some patients were treated with high-dose glucocorticoids or blood transfusions. It can occur at any time after treatment. If a patient develops anemia while taking ONAPGO, consider a hemolytic anemia workup; if it occurs, consider stopping treatment./p>p> strong classc-color-green>Impulse Control/Compulsive Behaviors:/strong> Patients may experience intense urges and inability to control them while taking ONAPGO. Because patients may not recognize these behaviors as abnormal, it is important to specifically ask about new or increased urges with ONAPGO. Consider dose reduction or stopping medication if urges develop./p>p> strong classc-color-green>Cardiac Events:/strong> ONAPGO can reduce resting systolic and diastolic blood pressure and may have potential to exacerbate cardiac (and cerebral) ischemia in patients with known cardiovascular and cerebrovascular disease. If patients develop signs and symptoms of cardiac or cerebral ischemia, re-evaluate continued ONAPGO use./p>p> strong classc-color-green>QTc Prolongation and Potential for Proarrhythmic Effects: /strong> There is a dose-related prolongation of QTc interval after apomorphine exposure similar to that achieved with therapeutic doses of ONAPGO. Drugs that prolong QTc have been associated with torsades de pointes and sudden death. Consider risks and benefits of ONAPGO treatment prior to initiating in patients with risk factors for prolonged QTc./p>p> strong classc-color-green>Hypersensitivity: /strong>Allergic reactions like urticaria, rash, pruritus, and/or manifestations of angioedema may occur due to ONAPGO or its sulfite excipient sodium metabisulfite, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes. Sulfite sensitivity prevalence is unknown, probably low, and seen more frequently in asthmatic people./p>p> strong classc-color-green>Fibrotic Complications: /strong>Retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, and cardiac valvulopathy have been reported with ergot-derived dopaminergic agents. Complete resolution does not always occur when drug is stopped. Reactions are believed to be related to ergoline structure. It’s unknown whether non-ergot derived dopamine agonists, such as ONAPGO, can cause these reactions./p>p> strong classc-color-green>Priapism: /strong>In clinical studies of intermittent apomorphine injection, painful erections were reported in 3 of 361 men treated with intermittent subcutaneous injection, and one patient withdrew from therapy because of priapism; although no patients in the clinical studies required surgical intervention, severe priapism may require surgical intervention./p>p classc-color-blue> strong>ADVERSE REACTIONS/strong>/p>p> Most common adverse reactions (incidence ≥10% on ONAPGO and at least twice the rate of placebo) were infusion site nodule, nausea, somnolence, infusion site erythema, dyskinesia, headache, and insomnia./p>p classmb-5>Please see full a classhcp_ISI_PI_link hcp-color-blue href/onapgo_PI.pdf target_blank>Prescribing Information/a>./p>/div> /div>/div> /div>/article> /div> /div>div idblock-onapgohcp-theme-referenceshomepage data-block-plugin-idblock_content:d2aa8ea2-6084-451f-b5d2-1f37755b9012 classblock block-block-content block-block-contentd2aa8ea2-6084-451f-b5d2-1f37755b9012> div classcontent> div classfield field--name-field-p-block-content-flex field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classcomponent-responsive-columns paragraph paragraph--type--component-responsive-columns paragraph--view-mode--default > div classinner-content-wrapper no-gutters> div classrow field__items no-gutters> div classpartial-responsive-column col paragraph paragraph--type--partial-responsive-column paragraph--view-mode--default> div classfield field--name-field-p-column-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classparagraph paragraph--type--component-html-container paragraph--view-mode--default component-html-container > div classclearfix text-formatted field field--name-field-text-html field--type-text-long field--label-hidden field__item>p classf-size-15 f-lh-19 mb-2 c-color-black>strong classc-color-blue>References: 1./strong> ONAPGO. Package insert. SupernusPharmaceuticals, Inc. strong classc-color-blue>2./strong> Trenkwalder C, Chaudhuri KR, Garcia Ruiz PJ, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease: clinical practice recommendations. i>Parkinsonism Relat Disord/i>. 2015;21(9):1023-1030. strong classc-color-blue>3./strong> Data on file. Supernus Pharmaceuticals, Inc. strong classc-color-blue>4./strong> ONAPGO. Instructions for Use. Supernus Pharmaceuticals, Inc./p>/div> /div>/div> /div> /div> /div> /div> /div>/div> /div> /div> /div> /section> /div> /div> div idregion-sticky-isi> div classinner-content-wrapper> section classrow region region-sticky-isi> div idblock-onapgohcp-theme-content-sticky-isi data-block-plugin-identity_block:node classblock block-entity-block block-entity-blocknode> div classcontent> article regionsticky_isi classnode node--type-isi-page node--view-mode-sticky clearfix col component-isi> header classnode--heading-bar data-region-sticky-toggle> h3 classnode__title> span classfield field--name-title field--type-string field--label-hidden>IMPORTANT SAFETY INFORMATION/span> /h3> button aria-labelToggle Sticky Region classnode--region-toggle-btn data-region-sticky-toggle > i classfas>/i> /button> /header> div classnode__content clearfix> div classfield field--name-field-p-content field--type-entity-reference-revisions field--label-hidden field__item> div classparagraph paragraph--type--component-html-container paragraph--view-mode--default component-html-container > div classclearfix text-formatted field field--name-field-text-html field--type-text-long field--label-hidden field__item>div classshowContentSticky>p classc-color-blue mb-2 pr-3> strong> span classd-block d-sm-inline>IMPORTANT SAFETY INFORMATION/span> /strong>/p>p class> span classd-block c-color-blue mb-2>strong>CONTRAINDICATIONS/strong>/span>span classd-block mb-2> Concomitant use of ONAPGO with 5HTsub>3/sub> antagonists is contraindicated based on reports of profound hypotension and loss of consciousness span classbtn-read-more mb-3 rolebutton>Read More/span> /span>/p>/div>p class> span classd-block c-color-blue>strong>INDICATION/strong>/span>span classd-block> ONAPGO is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s Disease (PD)./span>/p>p classc-color-blue> strong>IMPORTANT SAFETY INFORMATION/strong>/p>p classc-color-blue mb-0> strong>CONTRAINDICATIONS/strong>/p>p> Concomitant use of ONAPGO with 5HTsub>3/sub> antagonists is contraindicated based on reports of profound hypotension and loss of consciousness when ONAPGO was administered with ondansetron./p>p> ONAPGO is contraindicated in patients who have demonstrated hypersensitivity/allergic/anaphylactic reaction to it or any of its excipients, including sulfite (i.e., sodium metabisulfite)./p>p classc-color-blue> strong>WARNINGS AND PRECAUTIONS/strong>/p>p> strong classc-color-green>Serious Adverse Reactions After Intravenous Administration:/strong> Subcutaneous use only; thrombus formation and pulmonary embolism have followed intravenous administration./p>p> strong classc-color-green>Nausea and Vomiting: /strong> ONAPGO is known to cause nausea and vomiting (may be severe) when administered at recommended doses. Antiemetics with anti-dopaminergic actions have the potential to worsen PD symptoms. Consider starting therapy, without antiemetics, at 1 mg and titrate based upon effectiveness and tolerance./p>p> strong classc-color-green>Falling Asleep During Activities of Daily Living (ADL) and Somnolence: /strong>Somnolence is commonly associated with ONAPGO. Before initiating treatment, advise patients of risk and assess for factors that can increase it. If significant daytime sleepiness develops or patients fall asleep during ADL, ONAPGO should ordinarily be stopped. If continued, advise patients not to drive and avoid other potentially dangerous activities. There is insufficient information to determine if dose reduction will eliminate episodes of falling asleep during ADL./p>p> strong classc-color-green>Syncope/Hypotension/Orthostatic Hypotension:/strong> ONAPGO may cause orthostatic hypotension at any time, but especially during dose escalation. Patients should avoid alcohol when using ONAPGO and lie down before and after taking sublingual nitroglycerin. Other vasodilators and antihypertensives may also increase hypotensive effects. Monitor blood pressure in patients taking concomitant antihypertensive medications or vasodilators./p>p> strong classc-color-green>Falls: /strong>Patients with PD are at risk of falling due to underlying postural instability, possible autonomic instability, and syncope caused by blood pressure lowering effects of PD drugs. ONAPGO may increase risk of falling by simultaneously lowering blood pressure and altering mobility./p>p> strong classc-color-green>Infusion Site Reactions and Infections: /strong> Reactions have been reported including nodules, erythema, hematomas, inflammation, pruritus, swelling, discoloration, hemorrhage, hypersensitivity, induration, edema, pain, rash, or bruising. If an infection is suspected, such as cellulitis, which was reported, the cannula should be removed from the infusion site and a new cannula placed at a new infusion site. In the event of a prolonged interruption of treatment with ONAPGO, the patient should be prescribed oral medications to treat their PD./p>p> strong classc-color-green>Hallucinations/Psychotic-Like Behavior: /strong> Patients with a major psychotic disorder should ordinarily not be treated with ONAPGO due to risk of exacerbating psychosis. Also, certain medications used to treat psychosis may exacerbate symptoms of PD and decrease effectiveness of ONAPGO./p>p>strong classc-color-green>Dyskinesia: /strong>ONAPGO may cause dyskinesia or exacerbate pre-existing dyskinesia./p>p> strong classc-color-green>Hemolytic Anemia: /strong>Hemolytic anemia requiring hospitalization has been reported. Many cases included positive Coombs test. Severe anemia, angina, and dyspnea have occurred. Some patients were treated with high-dose glucocorticoids or blood transfusions. It can occur at any time after treatment. If a patient develops anemia while taking ONAPGO, consider a hemolytic anemia workup; if it occurs, consider stopping treatment./p>p> strong classc-color-green>Impulse Control/Compulsive Behaviors:/strong> Patients may experience intense urges and inability to control them while taking ONAPGO. Because patients may not recognize these behaviors as abnormal, it is important to specifically ask about new or increased urges with ONAPGO. Consider dose reduction or stopping medication if urges develop./p>p> strong classc-color-green>Cardiac Events:/strong> ONAPGO can reduce resting systolic and diastolic blood pressure and may have potential to exacerbate cardiac (and cerebral) ischemia in patients with known cardiovascular and cerebrovascular disease. If patients develop signs and symptoms of cardiac or cerebral ischemia, re-evaluate continued ONAPGO use./p>p> strong classc-color-green>QTc Prolongation and Potential for Proarrhythmic Effects: /strong> There is a dose-related prolongation of QTc interval after apomorphine exposure similar to that achieved with therapeutic doses of ONAPGO. Drugs that prolong QTc have been associated with torsades de pointes and sudden death. Consider risks and benefits of ONAPGO treatment prior to initiating in patients with risk factors for prolonged QTc./p>p> strong classc-color-green>Hypersensitivity: /strong>Allergic reactions like urticaria, rash, pruritus, and/or manifestations of angioedema may occur due to ONAPGO or its sulfite excipient sodium metabisulfite, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes. Sulfite sensitivity prevalence is unknown, probably low, and seen more frequently in asthmatic people./p>p> strong classc-color-green>Fibrotic Complications: /strong>Retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, pleural thickening, and cardiac valvulopathy have been reported with ergot-derived dopaminergic agents. Complete resolution does not always occur when drug is stopped. Reactions are believed to be related to ergoline structure. It’s unknown whether non-ergot derived dopamine agonists, such as ONAPGO, can cause these reactions./p>p> strong classc-color-green>Priapism: /strong>In clinical studies of intermittent apomorphine injection, painful erections were reported in 3 of 361 men treated with intermittent subcutaneous injection, and one patient withdrew from therapy because of priapism; although no patients in the clinical studies required surgical intervention, severe priapism may require surgical intervention./p>p classc-color-blue> strong>ADVERSE REACTIONS/strong>/p>p> Most common adverse reactions (incidence ≥10% on ONAPGO and at least twice the rate of placebo) were infusion site nodule, nausea, somnolence, infusion site erythema, dyskinesia, headache, and insomnia./p>p classmb-5>Please see full a classhcp_ISI_PI_link hcp-color-blue href/onapgo_PI.pdf target_blank>Prescribing Information/a>./p>/div> /div>/div> /div>/article> /div> /div> /section> /div> /div> div idregion-modals-flexible> section classrow region region-modals-flexible> !-- Modal -->div idblock-onapgohcp-theme-modalsignupform data-block-plugin-idblock_content:420d7c6e-553c-45db-8159-acdf4b4841b2 classmodal modal-flexible fade block block-block-content block-block-content420d7c6e-553c-45db-8159-acdf4b4841b2 data-disable-backdrop-clicksfalse tabindex-1 roledialog aria-hiddentrue> div classmodal-dialog modal-dialog-scrollable roledocument> div classmodal-content> div classmodal-header> button typebutton classclose data-dismissmodal aria-labelClose> span aria-hiddentrue>×/span> /button> /div> div classmodal-body> div classfield field--name-field-p-modal-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classcomponent-responsive-columns paragraph paragraph--type--component-responsive-columns paragraph--view-mode--default > div classinner-content-wrapper > div classrow field__items > div classpartial-responsive-column col paragraph paragraph--type--partial-responsive-column paragraph--view-mode--default> div classfield field--name-field-p-column-content field--type-entity-reference-revisions field--label-hidden field__items> div classfield__item> div classparagraph paragraph--type--component-block paragraph--view-mode--default component-block-container onapgo-form > div idblock-modalonapgohcpsignupform data-block-plugin-idmodal_onapgo_sign_up_hcp_form classblock block-mvp-forms-onapgo block-modal-onapgo-sign-up-hcp-form> div classcontent> form classjquery-validation-form validation-ajax-button-v2 forms-v2 component-form data-drupal-selectormodal-onapgo-sign-up-hcp-form action/ methodpost idmodal-onapgo-sign-up-hcp-form accept-charsetUTF-8> fieldset idedit-markup-titles classjs-form-item js-form-type-item form-type-item js-form-item-markup-titles form-item-markup-titles form-no-label form-group> h5 classh3 c-color-blue font-weight-700 col-lg-12 col-md-12 p-0>Sign up for more clinical information/h5> div classmb-3 mw-300>img alt src/ONAPGO_LOGO_2024_RGB_HCP.png classmw-250 width250 />/div> p classc-color-black mb-0>Fill out the fields below to receive more information on ONAPGO, including educational materials, patient support information, upcoming events, and more./p> /fieldset>div idonapgo-form-wrapper> fieldset idedit-markup-reqfields2 classjs-form-item js-form-type-item form-type-item js-form-item-markup-reqfields2 form-item-markup-reqfields2 form-no-label form-group> p classc-color-blue f-size-14 font-weight-100 mb-0>*Required field/p> /fieldset>div classrow>div classcol-12 col-md-6> fieldset classjs-form-item js-form-type-textfield form-type-textfield js-form-item-txt-field-first-name form-item-txt-field-first-name form-group> label foredit-txt-field-first-name classjs-form-required form-required>Your First Name/label> input data-rule-alphanumeric-v2true data-msg-alphanumeric-v2Please enter a valid first name data-regex-v2/^a-zA-Z0-9\s!@#$'`.+,\/-+$/ data-rule-requiredtrue data-msg-requiredPlease enter a valid first name data-drupal-selectoredit-txt-field-first-name typetext idedit-txt-field-first-name nametxt_field_first_name value size100 maxlength60 classform-text required form-control requiredrequired aria-requiredtrue /> /fieldset>/div>div classcol-12 col-md-6> fieldset classjs-form-item js-form-type-textfield form-type-textfield js-form-item-txt-field-last-name form-item-txt-field-last-name form-group> label foredit-txt-field-last-name classjs-form-required form-required>Your Last Name/label> input data-rule-alphanumeric-v2true data-msg-alphanumeric-v2Please enter a valid last name data-regex-v2/^a-zA-Z0-9\s!@#$'`.+,\/-+$/ data-rule-requiredtrue data-msg-requiredPlease enter a valid last name data-drupal-selectoredit-txt-field-last-name typetext idedit-txt-field-last-name nametxt_field_last_name value size100 maxlength60 classform-text required form-control requiredrequired aria-requiredtrue /> /fieldset>/div>/div>div classrow>div classcol-12 col-md-6> fieldset classjs-form-item js-form-type-select form-type-select js-form-item-credentials form-item-credentials form-group> label foredit-credentials classjs-form-required form-required>Specialty/label> select classform-select required custom-select form-text data-rule-requiredtrue data-msg-requiredPlease select a valid specialty data-drupal-selectoredit-credentials idedit-credentials namecredentials requiredrequired aria-requiredtrue>option value selectedselected>- Select -/option>option valueRPh>Pharmacist/option>option valueRN>Registered Nurse (RN)/option>option valueNU>Neurologist/option>option valueMDS>Movement Disorder Specialist (MDS)/option>option valueMD>MD - Other Specialty/option>option valueDNP>Doctor of Nursing Practice (DNP)/option>option valueCNP>Certified Nurse Practitioner (CNP)/option>option valueNP>Nurse Practitioner (NP)/option>option valuePA>Physician Assistant (PA)/option>option valueCNS>Clinical Nurse Specialist (CNS)/option>/select> /fieldset>/div>/div>div classrow>div classcol-12 col-md-6> fieldset classjs-form-item js-form-type-textfield form-type-textfield js-form-item-txt-field-email form-item-txt-field-email form-group> label foredit-txt-field-email classjs-form-required form-required>Your Email/label> input data-rule-email-v2true data-msg-email-v2Please enter a valid email data-regex-v2/^a-zA-Z0-9.!#$%&'*+\/?^_`{|}~-+@a-zA-Z0-9(?:a-zA-Z0-9-{0,61}a-zA-Z0-9)?(?:\.a-zA-Z0-9(?:a-zA-Z0-9-{0,61}a-zA-Z0-9)?)*$/ inputmodeemail data-rule-requiredtrue data-msg-requiredPlease enter a valid email data-drupal-selectoredit-txt-field-email typetext idedit-txt-field-email nametxt_field_email value size100 maxlength254 classform-text required form-control requiredrequired aria-requiredtrue /> /fieldset>/div>div classcol-12 col-md-6> fieldset classjs-form-item js-form-type-textfield form-type-textfield js-form-item-txt-field-emailconfirm-modal form-item-txt-field-emailconfirm-modal form-group> label foredit-txt-field-emailconfirm-modal classjs-form-required form-required>Confirm Email/label> input data-rule-email-v2true data-msg-email-v2Please enter a valid email data-regex-v2/^a-zA-Z0-9.!#$%&'*+\/?^_`{|}~-+@a-zA-Z0-9(?:a-zA-Z0-9-{0,61}a-zA-Z0-9)?(?:\.a-zA-Z0-9(?:a-zA-Z0-9-{0,61}a-zA-Z0-9)?)*$/ inputmodeemail data-rule-requiredtrue data-msg-requiredPlease enter a valid email data-rule-equaltoname'txt_field_email' data-msg-equaltoPlease enter a valid email data-drupal-selectoredit-txt-field-emailconfirm-modal typetext idedit-txt-field-emailconfirm-modal nametxt_field_emailconfirm_modal value size100 maxlength254 classform-text required form-control requiredrequired aria-requiredtrue /> /fieldset>/div>/div>div classrow>div classcol-12 col-md-6> fieldset classjs-form-item js-form-type-textfield form-type-textfield js-form-item-txt-zipcode form-item-txt-zipcode form-group> label foredit-txt-zipcode classjs-form-required form-required>ZIP Code/label> input data-rule-zipcode-v2true data-msg-zipcode-v2Please enter a valid ZIP code data-regex-v2/^0-9{5}(- ?0-9{4})?$/ inputmodetel data-rule-requiredtrue data-msg-requiredPlease enter a valid ZIP code data-drupal-selectoredit-txt-zipcode typetext idedit-txt-zipcode nametxt_zipcode value size60 maxlength10 classform-text required form-control requiredrequired aria-requiredtrue /> /fieldset>/div>/div>div classrow>div classcol-12 col-md-6> fieldset classjs-form-item js-form-type-textfield form-type-textfield js-form-item-npi-id-number form-item-npi-id-number form-group> label foredit-npi-id-number>NPI ID Number/label> input data-rule-tendigits-v2true data-msg-tendigits-v2Please enter a valid NPI ID Number data-regex-v2/^\d{10}$/ inputmodenumeric data-rule-npi_id_numberoptional data-msg-npi_id_numberPlease enter a valid NPI ID Number data-drupal-selectoredit-npi-id-number typetext idedit-npi-id-number namenpi_id_number value size25 maxlength10 classform-text form-control /> /fieldset>/div>/div>div classrow>div classcol-12 col-md-6> fieldset idedit-markup-npi-number classjs-form-item js-form-type-item form-type-item js-form-item-markup-npi-number form-item-markup-npi-number form-no-label form-group> p classmy-0 c-color-blue f-size-14 mt-n3>span classtooltip-copy>Forgot your National Provider Identifier?/p>p classmy-0>a hrefhttps://npiregistry.cms.hhs.gov/ classtext-nowrap look-here-btn font-weight-700 c-color-blue f-size-14 target_blank>Look it up herespan classml-1 f-size-12 icon-onapgo-triangle-right>/span>/a>/span>/p> /fieldset>/div>/div>div classg-recaptcha recaptcha-v2 data-sitekey6Lc_RrUZAAAAAIgBNC_Y6SEASgiYrITqV-ERoDzF data-callbackrecaptchaSuccess data-expired-callbackrecaptchaExpired data-error-callbackrecaptchaError data-sizeinvisible data-drupal-selectoredit-recaptcha>/div>/div>br>input autocompleteoff data-drupal-selectorform-idfsbiw6zfym1ek72xm2mfqkoaib3mazq4fva9gltee typehidden nameform_build_id valueform-IdfsBiW6ZFYm1Ek72Xm2mFQKoaiB3mAzQ4fVa9gLteE classform-control />input data-drupal-selectoredit-modal-onapgo-sign-up-hcp-form typehidden nameform_id valuemodal_onapgo_sign_up_hcp_form classform-control />div data-drupal-selectoredit-actions classform-actions js-form-wrapper form-group idedit-actions>div classsubmit mt-0 mb-0>button classbtn btn-primary-yellow btn-primary-solid1 px-5 button js-form-submit form-submit btn-primary data-drupal-selectoredit-submit typesubmit idedit-submit nameop valueSIGN UP NOW>SIGN UP NOW/button>input styledisplay:none classform-ajax-button-v2 button js-form-submit form-submit form-control data-drupal-selectoredit-validation-hack typesubmit idedit-validation-hack nameop valuevalidated />/div>div classprivacy-policy pt-5 mb-0>p classf-size-md-21 font-weight-600 c-color-blue mb-0>Terms and conditions/p> p classmb-3> By clicking Sign Up Now, I agree to the following: I would like to receive news and updates about Supernus products, clinical trials, research opportunities, programs, and other information that may be of interest to me. For more information about Supernus’ privacy practices and your privacy choices, view our a target_blank classbtn-link text-nowrap hrefhttps://www.supernus.com/privacy-policy>Privacy Policy/a>. /p> p classf-size-14 c-color-blue>This site is protected by reCAPTCHA and the Google a classbtn-link text-nowrap f-size-14 font-weight-700 hrefhttps://policies.google.com/privacy target_blank>Privacy Policy/a> and a hrefhttps://policies.google.com/terms target_blank classbtn-link text-nowrap f-size-14 font-weight-700>Terms of Service/a> apply./p> /div>/form> /div> /div> /div>/div> /div> /div> /div> /div> /div>/div> /div> /div> /div> /div>/div> /section> /div> /div> /div> footer classglobal-footer> div classglobal-footer__main> div classcontainer-fluid> div classinner-content-wrapper> div classglobal-footer__middle global-footer__section row> div classcol-12 col-md-4 col-lg-3> section classrow region region-footer-first-column> div classcol> div idblock-onapgohcp-theme-footerlogo data-block-plugin-idblock_content:f4e78f2d-79ee-4044-8976-c59aa10f8f66 classblock block-block-content block-block-contentf4e78f2d-79ee-4044-8976-c59aa10f8f66 logos-block row> div classcontent row> div classlogo-container col-11> a hrefhttps://www.supernus.com target_blank classsupernus-footer-logo pl-0 pl-md-3> div classfield field--name-field-brand-logo field--type-image field--label-hidden field__item> img loadinglazy src/sites/g/files/othskp1921/files/styles/large/public/2020-07/Supernus-logo.png?itok7EajaBNs width480 height107 altSupernus Pharmaceuticals classimage-style-large />/div> /a> /div> /div> /div> /div> /section> /div> div classcol-12 col-md-8 col-lg-9> section classrow region region-footer-second-column> div classcol> nav rolenavigation aria-labelledbyblock-onapgohcp-theme-footerlinks-menu idblock-onapgohcp-theme-footerlinks data-block-plugin-idsystem_menu_block:footer-links classblock block-menu navigation menu--footer-links> h2 classsr-only idblock-onapgohcp-theme-footerlinks-menu>Footer Links/h2> ul blockblock-onapgohcp-theme-footerlinks regionfooter_second_column classclearfix nav navbar-nav> li classnav-item> a hrefhttps://www.supernus.com/contact-us target_blank classnav-link nav-link-https--wwwsupernuscom-contact-us>Contact Us/a> /li> li classnav-item> a hrefhttps://www.supernus.com/privacy-policy target_blank classnav-link nav-link-https--wwwsupernuscom-privacy-policy>Privacy Policy/a> /li> li classnav-item> a hrefhttps://www.supernus.com/terms-of-use target_blank classnav-link nav-link-https--wwwsupernuscom-terms-of-use>Terms of Use/a> /li> li classnav-item> a href/sitemap classnav-link nav-link--sitemap data-drupal-link-system-pathnode/156>Sitemap/a> /li> /ul> /nav>div idblock-onapgohcp-theme-footerdisclaimer data-block-plugin-idblock_content:abedb2eb-5926-436a-9f05-d931d89542df classblock block-block-content block-block-contentabedb2eb-5926-436a-9f05-d931d89542df> div classcontent> div classclearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item>p classmy-1 styleline-height: 1rem;>MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc. is the exclusive licensee and distributor of ONAPGO in the United States and Its territories. © 2025. ONAPGO is a trademark of BRITUSWIP. Circle of Care is a trademark of MDD US Operations, LLC. span classtext-nowrap>SPN.830.2022-0076 04/25./span>/p>/div> /div> /div>div classviews-element-container block block-views block-views-blockepass-veeva-number-block-1 idblock-onapgohcp-theme-views-block-epass-veeva-number-block-1 data-block-plugin-idviews_block:epass_veeva_number-block_1> div classcontent> div regionfooter_second_column>div classview view-epass-veeva-number view-id-epass_veeva_number view-display-id-block_1 js-view-dom-id-83e713d932a2260181988deeeef014d33a0a3f3a8991fc3900db2bd49dd74465> div classview-content row> div classcol views-row> /div> /div> /div>/div> /div> /div> /div> /section> /div> /div> /div> /div> /div> /footer> /div>/div> /div> script src/sites/g/files/othskp1921/files/js/js_6vg4aIMaI5w70SQ6vY2vCcZUCOpaZO3jUuow6uxHmgg.js?scopefooter&delta0&languageen&themeonapgohcp_theme&includeeJx1j-EKgzAMhF-oWtgLhVRqrUubrkllvv10MsZk_vkgueO4c8wqWrGAw1oj20DskDrRlWIOZuDqbczqa0bq50fzde1HrskE5kAeFIMNG853jzM-f5_JpKVAIdQ9AHaIfROWG8zyT24aKWr0suucsQSehgI6-eTtUadLKHcjrWwdm3wDDo_7DLx0nBZf2QrTOkYieQH_K3p7>/script>script srchttps://www.google.com/recaptcha/api.js?onloadonloadRecaptchaCallback&renderexplicit defer async>/script>script src/sites/g/files/othskp1921/files/js/js_bPvBHSkmvy-EGQ14LkR83OMOmAPYC_6VCTsF3lutVVE.js?scopefooter&delta2&languageen&themeonapgohcp_theme&includeeJx1j-EKgzAMhF-oWtgLhVRqrUubrkllvv10MsZk_vkgueO4c8wqWrGAw1oj20DskDrRlWIOZuDqbczqa0bq50fzde1HrskE5kAeFIMNG853jzM-f5_JpKVAIdQ9AHaIfROWG8zyT24aKWr0suucsQSehgI6-eTtUadLKHcjrWwdm3wDDo_7DLx0nBZf2QrTOkYieQH_K3p7>/script> /body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]